RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s COVID-19 research toolkit.
In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus that causes COVID-19. Conversely, the new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.
Although various hACE2 mouse models of lethal SARS-CoV-2 infection exist, the hACE2 AC22 lethality-resistant model is important because it permits study of sublethal infection. Most humans infected with SARS-CoV-2 survive, and an animal model which replicates sublethal disease and recovery is needed. The hACE2 AC22 mouse provides a longer study window to assess drug efficacy compared to lethal infection models.
“While vaccines bring hope of an end to the pandemic, research on COVID-19 is still needed,” shared Dr. Michael Seiler, vice president of commercial models at Taconic. “There is a huge population of people who have now had the disease. We need models that also survive this disease long enough to aid in replicating that human condition. It cannot be overstated just how important this new AC22 model is in enabling that research.”
Study ready cohorts of animals are available for immediate ordering.
To learn more about hACE2 mice or Taconic's Coronavirus Toolkit, please contact Taconic at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia, and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact: Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com